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ABSTRACT: Owing to the central role of osteoclasts in bone physiology and remodeling, manipulation of their maturation process
provides a potential therapeutic strategy for treating bone diseases. To investigate this, we genetically inhibited the Notch signaling
pathway in the myeloid lineage, which includes osteoclast precursors, using a dominant negative form of MAML (dnMAML) that inhibits
the transcriptional complex required for downstream Notch signaling. Osteoclasts derived from dnMAML mice showed no significant
differences in early osteoclastic gene expression compared to the wild type. Further, these demonstrated significantly lowered resorption
activity using bone surfaces while retaining their osteoblast stimulating ability using ex vivo techniques. Using in vivo approaches, we
detected significantly higher bone formation rates and osteoblast gene expression in dnMAML cohorts. Further, these mice exhibited
increased bone/tissue mineral density compared to wild type and larger bony calluses in later stages of fracture healing. These
observations suggest that therapeutic suppression of osteoclast Notch signaling could reduce, but not eliminate, osteoclastic resorption
without suppression of restorative bone remodeling and, therefore, presents a balanced paradigm for increasing bone formation,
regeneration, and healing. © 2019 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 37:2089–2103, 2019
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Fracture healing is a complex multi‐phase process. At
the early stage of healing, osteoclasts remodel the
fracture margin in preparation for callus formation.1–3
As the initially cartilaginous soft callus calcifies into a
fracture‐stabilizing bony callus, osteoclasts return, and
alongside osteoblasts, remodel the callus until physio-
logical bone architecture is restored. Should fracture
healing proceed inefficiently, however, the discontinuity
caused by the fracture may persist or, following
apparent healing, there may be persistent structural
weakness that can contribute to re‐fracture.4,5 This is of
concern in aged individuals, where the efficiency of the
bone healing process is diminished. Current strategies
to improve skeletal healing include local surgical
delivery of osteo‐inductive materials or proteins and
systemic delivery of anti‐resorptive or anabolic
therapy.6 However, none of these therapies accelerate
normal fracture healing nor are they recommended for
long‐term use as re‐fracture preventatives.7–9 New
approaches based on a clear mechanistic under-
standing of bone biology and regeneration represent
opportunities to address these limitations.
Bone resorbing osteoclasts are formed from hemato-
poietic progenitors of the monocyte/macrophage lineage
in a multi‐step process, which includes progenitor
proliferation, expression of functional genes, and fusion
into mature, resorption‐capable giant cells.10,11 In
addition to their role as bone resorbing cells, osteoclasts
promote the differentiation of bone‐forming osteo-
blasts.12–15 This coupling role is apparent in both
genetic and pharmacologic suppression of osteoclast
numbers, which result in a coupled reduction in
osteoblasts.12,13 Conversely, approaches that inhibit
osteoclast activity while preserving osteoclast number
preserve osteoblast function.16 Thus, understanding of
mechanisms of osteoclast function (as opposed to those
of initial differentiation or survival) are of interest, as
inhibition of osteoclast maturation may reduce resorp-
tion while preserving osteoblast activity and physiolo-
gical remodeling.
One such osteoclast maturation‐controlling system
is Notch signaling. We, along with other research
groups, have demonstrated that Notch signaling plays
a bi‐phasic role in osteoclastogenesis, in which, prior to
commitment, stimulation of Notch signaling inhibits
osteoclast differentiation. After commitment with re-
ceptor activator of nuclear factor κ‐Β ligand (RANKL),
however, Notch signaling is required for final matura-
tion and full functionality.17–21 Notch signaling is
initiated by binding of one of five ligands to one of
four Notch receptors. This binding releases the intra-
cellular portion of the receptor (NICD), which translo-
cates to the nucleus and binds recombination signal
binding protein for immunoglobulin kappa J region
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(RBPJκ), a transcriptional regulator, to displace co‐
repressors and recruit co‐activators. Mastermind‐like
(MAML) is a crucial transcriptional co‐activator that
serves as an interface between NICD and RBPJκ.22–24
In the present study, inhibition of Notch signaling was
achieved via expression of dnMAML, which competi-
tively inhibits transcription complex formation by
binding NICD and RBPJκ, but no other co‐activators
(Fig. 1A).22,25 dnMAML was expressed in the myeloid
lineage, which includes osteoclasts and their precur-
sors, via cross between Rosa‐dnMAML mice, which
carry a LoxP‐STOP‐LoxP‐dnMAML expression cas-
sette, and mice that express Cre recombinase under
the control of the lysozyme M (LysM), promoter.
We asked, (i) is osteoclast Notch signaling required
for bone remodeling and architecture at physiological
baseline, and (ii) will inhibition of osteoclast Notch
signaling improve fracture healing?
METHODS AND MATERIALS
Mice Breeding
Experimental mice cohorts were generated by mating
homozygous LysMCre/Cre (B6.129P2‐Lyz2tm1(cre)Ifo/J;
Jackson Labs, Bar Harbor, ME) with heterozygous
Rosafl‐STOP‐fl‐dnMAML/+ mice (C57/Bl6 genetic background).
The genotypes of the offspring obtained were LysMCre/
+/Rosafl‐STOP‐fldnMAML/+ (dnMAML mice) and LysMCre/
+/Rosa+/+ (control or WT) (Fig. 1B). The LysM‐Cre26
mouse has been used previously in multiple studies to
investigate the roles of specific molecules in osteoclast
differentiation without confounding effects during em-
bryonic development.27–29
Osteoclast Culture and Maintenance
Osteoclast precursors were cultured and differentiated
as previously described.21,30 Briefly, bone marrow from
femurs and tibias were flushed using α‐minimum
essential medium (α‐MEM) and centrifuged. Cells
were later incubated overnight to allow adherent cells
to attach to the plate. Next day, non‐adherent cells were
transferred to new plates with 35 ng/ml recombinant
mouse monocyte/macrophage colony‐stimulating factor
(MCSF) (BioLegend, San Diego, CA). Upon 70%
confluency, adherent osteoclast precursors were har-
vested using Accutase and later seeded at a density of
approximately 26,000 cells per cm2 in α‐MEM with
35 ng/ml MCSF and 100 ng/ml recombinant mouse
RANKL (Shenanandoah Biotechnology, Warwick, PA).
Differentiation medium was replaced every other day.
After a period of 3–4 days, osteoclastogenesis was
completed and multinuclear cells were observed. The
osteoclasts were later tartrate‐resistant acid phospha-
tase (TRAP) stained according to the kit instructions
(Sigma‐Aldrich, St. Louis, MO) to evaluate the enzy-
matic activity or lysed for RNA extraction.
Fluorescence Microscopy
Osteoclasts were differentiated on cover glass circles
#1.5, 12mm (Electron Microscopy Sciences, Hatfield,
PA) and placed into 24‐well plates. After a period of 4
days, cells were fixed using 4% paraformaldehyde for
10min at room temperature (RT) and washed with
phosphate‐buffered saline (PBS) twice. 0.1% Triton X‐
100 was added for 5min with subsequent washing
using PBS. Cells were then blocked in 1% bovine serum
albumin for 30min and stained using Alexa Fluor 594
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Figure 1. Genetic manipulation of Notch signaling in osteoclasts. (A) Trans‐activation of Notch signaling in the receiving cell is
initiated via interaction between Notch receptor and ligand (Jagged1 or Delta‐like1) presented by the transmitting cell. This initiates
proteolytic cleavage events that release the Notch intracellular domain (NICD) that translocates to the nucleus and forms a
transcriptional complex with MAML and CSL. Notch signaling can be inhibited at the receptor level with DAPT, a γ‐secretase inhibitor
that inhibits NICD release, or at the transcriptional level by either expressing dominant negative MAML (dnMAML) or treating with
SAHM1, a peptide dnMAML mimetic. (B) In this study, we inhibited Notch signaling in osteoclast precursors via Lysozyme M promoter‐
driven dnMAML expression. Mice with genotypes LysM‐Cre/‐ dnMAML−/− (WT) and LysM‐Cre/‐ dnMAMLMye+/− (dnMAML) were utilized
for subsequent studies. CSL, CBF1/Suppressor of Hairless/LAG‐1. [Color figure can be viewed at wileyonlinelibrary.com]
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labeled Phalloidin (Molecular Probes, Eugene, OR)
with 5 µl in 200 µl PBS/well. The samples were
incubated for 30min in dark. Cells were washed using
PBS and then coverslips mounted on clear glass slides
after addition of Prolong Gold antifade reagent with
4′,6‐diamidino‐2‐phenylindole (Thermo Fisher Scien-
tific, Waltham, MA). Finally, the coverslips were sealed
using nail paint and Images were acquired using a
Nikon Eclipse fluorescence microscope (Nikon, Mel-
ville, NY).
RNA Isolation and Quantitative Polymerase Chain
Reaction (PCR)
RNA was extracted using TRIzol from Thermo Fisher
Scientific as per the manufacturer’s instructions.21
RNA concentration was determined using a spectro-
photometer and 1 µg of RNA was used as starting
material for complementary DNA (cDNA) preparation.
Total RNA was reverse transcribed using SuperScript
VILO (Thermo Fisher Scientific). cDNA was then used
as a template for amplification using SYBR Green in a
ViiA7 Real time PCR system (Thermo Fisher Scien-
tific). Each of the samples were set up in triplicates and
the experiments were repeated at least thrice for data
integrity and accuracy. Gene expression was normal-
ized to 18S. The list of primers is provided in Table 1.
Jagged 1 Stimulation and Hes1 Expression
Notch signaling was stimulated using immobilized
Jagged1 as previously described.21,30 Goat immunoglo-
bulin G (Jackson Immunology, West Grove, PA) and
Jagged‐1, a Notch ligand (R&D Systems, Minneapolis,
MN) were made in PBS at a concentration of 10 µg/ml
and added to 48‐well plates. Wells were then washed
using PBS and later 26,000 osteoclast precursors were
seeded (24 h pre‐exposure to either MCSF alone or both
MCSF and RANKL). Plates were incubated for at least
24 h prior to harvesting the cells for RNA extraction and
analysis of Hes1 gene expression.
Mineral Dissolution Assay
Nearly, 50,000 cells were seeded into a 24‐well Osteo‐
assay plate (Corning Life Sciences, Tewksbury, MA)
coated with calcium phosphate. Both WT and dnMAML
osteoclast precursors were seeded and later treated
with MCSF or MCSF and RANKL for a total of 5 days.
Media were replenished alternatively as described
earlier. The remaining mineral was Von Kossa stained
as per the protocol described.21 Cells were washed with
PBS and incubated in 10% bleach for 5min followed by
washing twice with deionized water. Three hundred
microliters of 5% silver nitrate was added to the plate
and incubated at RT for 30min. Wells were then
washed thoroughly using deionized water. Later,
300 µl of 5% sodium carbonate made in formalin was
added and incubated for another 5min at RT. Finally,
the solution was removed from the wells and air dried.
Plates were then scanned and quantified using ImageJ
software (NIH, Bethesda, MD).
Pit Formation Assay and Determination of TRAP Activity
Cortical bone slices (Immunodiagnostic Systems, East
Boldon, UK) were purchased for in vitro assessment of
osteoclastic bone resorption using pit formation assay
as per the procedure described with slight modifica-
tions.31–33 Bone chips were sterilized under ultraviolet
for at least 2 h and then washed with media before
placing in 96‐well plates. Twenty thousand cells per
two hundred microliter of (WT and dnMAML) were
seeded onto the bone slices containing either MCSF or
MCSF and RANKL for a total of 12 days. Conditioned
media was collected and replenished with new media
every third day. The former was then stored at −20°C
for further analysis of TRAP and type I collagen C‐
telopeptide (CTX‐1) levels. At day 12th, osteoclasts
were removed, and slices were stained with 1%
toluidine blue in 1% sodium borate solution. Bone
slices were dried and imaged using Nikon Eclipse light
microscope. Pits were counted and measured using
ImageJ software. TRAP/TRACP activity was deter-
mined34,35 using TRAP solution buffer consisting of L‐
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Table 1. List of Primers Used for Semiquantitative Reverse Transcription Polymerase Chain Reaction
Sl. No. Name Forward Reverse
1 TRAP/ACP5 CAGCTCAGTTGGGTAGCACA AGCCACAAATCTCAGGGTGG
2 CSTK CAGTGTTGGTGGTGGGCTAT CATGTTGGTAATGCCGCAGG
3 MMP9 CAGACGTGGGTCGATTCCAA TCATCGATCATGTCTCGCGG
4 Wnt10b ACCACGACATGGACTTCGGAGA CCGCTTCAGGTTTTCCGTTACC
5 Hes1 GAGGCTGCCAAGGTTTTTGG ACTTTACGGGTAGCAGTGGC
6 ALP CCAGAAAGACACCTTGACTGTGG TCTTGTCCGTGTCGCTCACCAT
7 OSX ATGGCGTCCTCTCTGCTTGA TTCCCCAGGGTTGTTGAGTC
8 OCN GCAATAAGGTAGTGAACAGACTCC CCATAGATGCGTTTGTAGGCGG
9 Runx2 CCTGAACTCTGCACCAAGTCCT TCATCTGGCTCAGATAGGAGGG
10 DC‐STAMP TTTGCCGCTGTGGACTATCTGC GCAGAATCATGGACGACTCCTTG
11 OC‐STAMP GGCTCAGAAGTTACCCACTGTC GGAGGTTGGTTGAGGACGAAGA
12 MAML CCAGCTTTGATGGCATATCTTCC CTACAGGGACACTGGAAGGGTT
13 18S GGTAACCCGTTGAACCCCAT CAACGCAAGCTTATGACCCG
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ascorbic acid, di‐sodium tartrate, 4‐nitrophenylpho-
sphate, and reaction buffer (1M acetate, 0.5% Triton
X‐100, 1M NaCl, 10mM ethylenediaminetetraacetic
acid pH = 5.5). Ten microliters of condition medium was
dispensed into a new 96‐well plate and 90 µl TRAP
solution buffer was added. The mix was incubated at
37°C for about 15min in the dark. The reaction was
stopped using 0.3 N NaOH, and absorbance was
measured at 405 nm using a BioTek spectrophotometer
(BioTek, Winooski, VT).
Determination of CTX‐1 and Osteocalcin Levels
CTX‐1 levels were measured in serum collected from 3‐
month‐old female and male (WT and dnMAML mice)
and conditioned medium collected from bone slices
using CTX‐I detection enzyme‐linked immunosorbent
assay (ELISA) kit (Chondrex, Inc., Redmond, WA). It is
based on a competitive assay system with a monoclonal
antibody, which recognizes conserved peptide se-
quences in mouse.36 Levels of osteocalcin, a bone
formation marker37 was evaluated using mouse osteo-
calcin ELISA (NBP2‐68151; Novus Biologicals, Cen-
tennial, CO) in serum collected from 3‐month old WT
and dnMAMLmice, respectively, as per the instructions
provided in the kit.
Osteoblast Culture Maintenance, Alkaline Phosphatase
(ALP) Activity, and Alizarin Staining
Adherent bone marrow stromal cells were cultured to
70% confluency. Cells were then harvested and then
seeded at a density of 30,000 cells per cm2. WT cells
were maintained in maintenance media (α‐MEM
supplemented with 10% fetal bovine serum, 1%
penicillin–streptomycin, 1% L‐glutamine, 1% non‐es-
sential amino acids), osteogenic media (maintenance
media + 10mM β‐glycerol phosphate + 50 µM ascorbate‐
2‐phosphate + 100 nM dexamethasone), osteogenic
media in combination with conditioned media collected
form either WT or dnMMAL osteoclasts (here condition
media was first concentrated using 3 kDa cut off
concentration filters (Millipore, Burlington, MA) and
then mixed in a ratio of 1:10 with osteogenic media), or
osteogenic media in combination with 30 ng/ml bone
morphogenetic protein 6 (BMP‐6) (R&D Systems).
Media were refreshed every third day. ALP activity
was measured by SensoLyte pNPP Alkaline Phospha-
tase Assay Kit (AnaSpec, Inc., Fremont, CA)38 as per
the manufacturer’s instructions. Mineralized nodules
were stained with alizarin red as per the protocol
described earlier.39
Skeletal Phenotyping
WT and dnMAML mice were given a subcutaneous
injection of calcein and alizarin red to label bone
mineralizing surfaces fluorescent green and red (9
and 2 days prior to euthanasia). Following euthanasia,
right femurs were fixed, decalcified, and sectioned.
Paraffin sections were TRAP‐stained for quantification
of osteoclast numbers. Left femurs were fixed,
embedded in polymethylmethacrylate, sectioned, and
stained using trichrome40,41 for quantification of osteo-
blasts per trabecular area and osteoblast surface per
bone surface. Unstained sections were imaged fluores-
cently for quantification of mineralizing surfaces and
determination of bone formation rate. Images were
acquired using a Nikon Eclipse fluorescence microscope
and analyzed using Osteomeasure software (Osteo-
Metrics, Atlanta, GA). Left tibias were fixed and
analyzed via µCT with subsequent mechanical testing.
RNA was extracted from right tibias for analysis of
osteoclast (TRAP, CSTK, MMP9, and Wnt10B) and
osteoblast gene expression (ALP, Osterix, Osteocalcin,
and Runx2), respectively.
Fracture Protocol and Surgery
Mice were fractured as per the protocol described
earlier.42 Briefly, a small incision was created around
the mouse’s knee and a 27‐gauge needle was placed in
the tibial tuberosity just above the patella for fracture
stabilization. Following pinning and incision, a trau-
matic 3‐point‐bend fracture was generated using a
modified guillotine (consists of a weight [220 g] sitting
7 cm above the metal lever). The setup of fracture
device is outlined in Figure S1. Mice were recovered
from anesthesia on a warm water pad and received a
subcutaneous dose of extended release buprenorphine
(0.5mg/kg) after the surgery, and then once every third
day. Animals were humanely euthanized for analysis at
10‐, 20‐, and 40‐days post fracture (DPF). Fracture
calluses were analyzed using µCT and histology.
MicroCT (μCT) Parameters43–46
Samples were imaged in a µCT scanner (model μCT50;
Scanco Medical, Wangen‐Brüttisellen, Switzerland). A
Gaussian low‐pass filter (σ = 0.8, support = 1) was used
for all analyses. Trabecular bone parameters were
measured by analyzing 150 slices of the distal meta-
physis. Cortical bone parameters were measured by
analyzing 50 slices in the mid‐diaphysis. A semi‐
automated contouring method was used to determine
the outer cortical bone perimeter. The distal metaphy-
seal regions were used for evaluation of bone volume,
total volume, bone volume/total volume, trabecular
number, trabecular thickness, trabecular spacing,
bone mineral density, and tissue mineral density while
mid‐diaphyseal regions for determining cortical thick-
ness, cortical bone mineral density, and cortical tissue
mineral density. Fractured tibias were quantified based
on region of interest of each callus and the following
parameters were determined: mineralized callus vo-
lume (BV), total callus volume (TV), mineralized callus
volume fraction (BV/TV), bone mineral density (BMD),
tissue mineral density (TMD), and average callus area.
The latter was calculated by counting the number of
slices multiplied by the size of the slice (0.006mm/slice)
to obtain the total length of the callus, and subse-
quently, average callus area was determined by
dividing bone volume to total callus length.
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Mechanical Testing
Following μCT, tibias were placed on the fixed supports
of 3‐point bending fixture (14mm span). The actuator
of testing system (DaynaMight; Instron Corp., Nor-
wood, MA) was centered above the medial region and
anterior sides facing forward and down, respectively. To
keep the bone in place a pre‐load of 2 N was applied. A
load at constant rate of 0.005mm/s was applied
centrally until failure occurred. The force–displacement
curve was then recorded for each sample and the
structural stiffness determined by measuring the slope
of curve at its linear portion. Additionally, ultimate
force (force at failure) was determined.
Histological Parameters
Femurs from the skeletal phenotyping group were
paraffin‐embedded and sectioned for TRAP staining.
Fracture callus sections were TRAP‐stained for quantifica-
tion of osteoclast numbers and Safranin O stained for
quantification of callus area and cartilage area. TRAP
staining was performed as per the protocol fromUniversity
of Rochester. Paraffin sections were first deparaffinized
using xylene and rehydrated through graded ethanol
(100%, 95%, and 80%) to distilled water. Slides were
then placed in pre‐warmed TRAP staining solution mix
(sodium acetate, tartaric acid, glacial acetic acid, fast Red
violet, and naphthol) for about an hour and rinsed in
distilled water. Slides were later counterstained with
0.02% Fast Green for 45 s and rinsed quickly in distilled
water followed by dehydration using ethanol (80%, 95%,
and 100%) with clearing in xylene. Slides were mounted
using Permount (Thermo Fisher Scientific) and imaged
using Nikon Eclipse light microscope. Osteoclasts were
counted using the Osteomeasure software. Safranin O
staining was performed as per the protocol described
earlier47–49 and from IHC world. Briefly, sections were
deparaffinized and hydrated. Slides were stained using
Weigert’s iron hematoxylin working solution, washed, and
then counterstained using fast green. Slides were rinsed
quickly in 1% acetic acid and then stained using 0.1%
Safranin O solution. Finally, the slides were dehydrated
andmounted as described above. Slides were imaged using
Nikon Eclipse light microscope. Cartilage and callus area
were determined using the Osteomeasure software.
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Figure 2. dnMAML suppresses Jagged1 induction of Hes1. Ex vivo generated osteoclasts from both WT and dnMAML mice were
subjected to Notch signaling stimulation via Jagged1 following culture with macrophage colony‐stimulating factor (MCSF) alone or
MCSF + RANKL. After 24 h of Jagged1 stimulus, relative expression of Hes1 was determined via quantitative reverse transcription
polymerase chain reaction (qRT‐PCR). (A) Schematic representation of Notch signaling stimulation via immobilized Jagged1. (B)
Relative expression of Hes1 (Notch target gene) following exposure to Jagged1 or immunoglobulin G (IgG) demonstrated that Jagged1
stimulation produced a robust increase in Hes1 expression that was blunted by dnMAML. MCSF +RANKL treatment also reduced
Jagged1‐stimulated Hes1 expression. (C) MAML gene expression analysis in osteoclasts and osteoblasts was performed using qRT‐PCR.
Relative levels of MAML were unchanged during the differentiation process for both the cell types. Jagged1 treatment, however,
significantly increased MAML expression in osteoclast precursors maintained with MCSF, but not MCSF +RANKL. Values represented
are mean± SD from at least three independent experiments. p value was calculated using Student t test (*p< 0.05). [Color figure can be
viewed at wileyonlinelibrary.com]
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Biological Variables and Data Analysis
Experiments were carried out in both male and
female animals as skeletal problems, fractures, and
healing issues affect both sexes. Skeletal pheno-
typing was performed in both 3‐ and 6‐month males
and female C57/BL6 mice cohorts whereas fractures
and other ex vivo work in 3‐month male and female
mice (WT and dnMAML).
Statistics
All experiments were performed at least thrice
independently and represented as mean ± SD. Stu-
dent t test was used for statistical analysis and
p < 0.05 was considered statistically significant.
Graphpad Prism 6.0 software (GraphPad, San Diego,
CA) was used for graphical representation of the
data. To increase rigor, analyses subject to
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Figure 3. Genetic inhibition of Notch signaling suppresses osteoclast maturation but does not impact early gene expression. Bone
marrow‐derived macrophages were collected from both wild‐type (WT) and dnMAML mice and differentiated into osteoclasts ex vivo. (A)
Tartrate‐resistant acid phosphatase (TRAP)‐stained osteoclasts (purple) in WT group were giant and well‐fused while osteoclasts from
Notch‐inhibited mice failed to fuse effectively and remained immature. (B) Quantification of TRAP‐stained multinuclear osteoclasts
showed a significant reduction in average number of osteoclasts in dnMAML group. (C) To delineate cytoskeletal reorganization, actin
filaments were assessed using Phalloidin staining. There were fewer and smaller osteoclasts in dnMAML group, but these cells still
demonstrated podosome belts, suggesting normal actin organization. (D) and (E) Expression analysis of osteoclastic marker genes (TRAP,
cathepsin K [CTSK], matrix metalloproteinase 9 [MMP9], and Wnt10b) and osteoclast‐specific fusion markers dendritic cell‐specific
transmembrane protein and osteoclast stimulatory transmembrane protein (DC‐STAMP and OC‐STAMP) ex vivo showed no significant
differences between the dnMAML and WT groups. Values represented are mean± SD from at least three independent experiments.
p value was calculated using Student t test (*p< 0.05). [Color figure can be viewed at wileyonlinelibrary.com]
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measurement variability (e.g., qPCR, ex vivo cel-
lular assays, serum measurements) were performed
in triplicate and those subject to evaluator varia-
bility (e.g., histomorphometry analysis) performed
in a blinded fashion.
Study Approval
Mice were housed and procedures carried out in facilities
provided by the University of Pennsylvania and the
Philadelphia VA Medical Center both of which are
AAALAC accredited. Procedures were approved by the
Institutional animal care and use Committee (IACUC) of
the University of Pennsylvania.
RESULTS
dnMAML Suppresses Jagged1 Induction of Hes1 in Bone
Marrow Macrophages and Pre‐Osteoclasts
To assess the functionality of dnMAML in osteoclast
precursors, cells from both WT and dnMAML mice
were subjected to Notch signaling stimulation via
immobilized Jagged1 after a 24‐h pre‐exposure to
either MCSF alone or MCSF + RANKL (Fig. 2A).
Twenty‐four hours of Jagged1 stimulation produced
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Figure 4. Genetic inhibition of Notch signaling reduces osteoclast resorptive function. (A) Osteoclast precursors generated ex vivo from
both wild‐type (WT) and dnMAML mice were differentiated and cultured on calcium phosphate coated surfaces for a period of 5 days.
Following culture, osteoclasts were removed and the remaining minerals were von Kossa stained and (B) quantified using ImageJ
software. dnMAML osteoclasts demonstrated significantly reduced resorptive activity compared with WT. (C) Osteoclast precursors were
seeded on bovine cortical bone slices in 96‐well plates and cultured in the presence of macrophage colony‐stimulating factor (MCSF) alone
or MCSF +RANKL for a period of 2 weeks. Conditioned media were collected every third day and tartrate‐resistant acid phosphatase
(TRAP) enzymatic activity was evaluated using pNPP chromogenic substrate. There was a significant reduction in TRAP activity in the
conditioned media of dnMAML osteoclasts cultured with MCSF +RANKL on days 6, 9, and 12. (D) CTX‐1, c‐terminal fragments of type I
collagen, levels were determined in condition media from WT and dnMAML osteoclasts. CTX‐1 levels were significantly reduced in
dnMAML osteoclasts cultured with MCSF +RANKL on days 6, 9, and 12. (E) At the conclusion of culture, bone slices were toluidine blue
stained to reveal the resorption pits. (F) Quantification showed a significant reduction in number of resorption pits from dnMAML
osteoclast cultures. Values represented are mean± SD from at least three independent experiments. p value was calculated using
Student t test (*p< 0.05). [Color figure can be viewed at wileyonlinelibrary.com]
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a robust induction of Hes1, a Notch target gene, in
both bone marrow macrophages and pre‐osteoclasts,
and this induction was blunted by the presence of
dnMAML (Fig. 2B). Interestingly, prior stimulation
of RANK signaling likewise reduced Hes1 transcrip-
tion, and this effect was further diminished by the
presence of dnMAML (Fig. 2B). We also estimated
the levels of MAML during the differenenciation of
both osteoclasts and osteoblasts. Levels of MAML
were relatively unaltered in both the osteoclasts and
osteoblasts (Fig. 2C). However, we observed a
significant difference in MAML expression levels
upon stimulation with Jagged 1 in MCSF alone
group whereas in MCSF + RANKL‐treated osteo-
clasts the levels of MAML were unchanged (with or
without Jagged 1 stimulation), as shown in
Figure 2C.
Notch Signaling Is Not Required for Early Osteoclast Gene
Expression
Osteoclasts derived from both WT and dnMAML
mice were subjected to TRAP staining. Osteoclasts
from WT were giant and fully mature while the
osteoclasts from dnMAML mice failed to fuse
effectively and remained immature (Fig. 3A).
Further, the number of mature osteoclasts were
significantly higher in the control group (Fig. 3B).
dnMAML cells, nevertheless, remained TRAP‐posi-
tive indicating a failure not in differentiation per se,
but fusion and maturation. To delineate cytoskeletal
reorganization and actin ring formation, actin fila-
ments were stained with phalloidin. While dnMAML
osteoclasts were smaller and fewer, those that did
form demonstrated normal podosome belts (Fig. 3C).
Gene expression analysis of early osteoclast marker
genes (TRAP, cathepsin K [CTSK], matrix metallo-
proteinase 9 [MMP9], and Wnt10b) found no
significant difference between WT and dnMAML
osteoclasts providing further evidence that Notch
signaling drives maturation rather than initial
differentiation of osteoclasts (Fig. 3D). The smaller
and immature osteoclasts observed in dnMAML
group indicated a possible defect in fusion process.
To address this, we carried out gene expression
analysis for fusion markers specific to osteoclasts
such as dendritic cell‐specific transmembrane pro-
tein and osteoclast stimulatory transmembrane
protein.11 The expression was relatively the same
between the two groups (Fig. 3E). This suggests that
dnMAML‐expressing osteoclasts do not have a defect
in gene expression required for differentiation
process. However, we do expect that the fusion
markers will be reduced at the protein or surface
level, but this needs to be investigated further.
dnMAML Expression Suppresses Osteoclast Activity
To measure osteoclast activity, WT and dnMAML osteo-
clasts were differentiated and cultured on calcium phos-
phate coated plates and bovine cortical bone slices. In both
instances, dnMAML osteoclasts demonstrated reduced
resorption areas (Fig. 4A, B, E, and F). In addition,
assessment of TRAP activity and C‐terminal CTX‐I frag-
ments in conditioned media revealed that dnMAML
osteoclasts secreted lower amounts of TRAP and digested
less collagen than their WT counterparts (Fig. 4C and D).
dnMAML Suppresses Osteoclast Activity Without
Impacting TRAP+ Cell Number or Gene Expression In Vivo
As measured by serum CTX‐I ELISA, dnMAML mice
(3‐month old males and females) demonstrated reduced
osteoclast activity compared with WT (Fig. 5A). To
assess whether this effect was a result of decreased
osteoclast number, TRAP staining was performed.
Histomorphometric analysis of TRAP‐stained sections
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Figure 5. Notch inhibition impairs resorptive activity in vivo without impacting tartrate‐resistant acid phosphatase (TRAP)+ cell
numbers and gene expression profiles. (A) CTX‐1 levels in serum obtained from 3‐month‐old male and female wild‐type (WT) and dnMAML
mice were significantly reduced in dnMAML mice suggesting reduced resorptive activity. No differences in serum osteocalcin (OCN) levels
were observed between the two groups suggesting comparable osteoblast activity. TRAP+ cell numbers and expression profile of osteoclastic
marker genes (TRAP, cathepsin K [CTSK], matrix metalloproteinase 9 [MMP9], and Wnt10b) were analyzed in (B) 3‐month‐old males and
(C) 3‐month‐old females using TRAP staining and quantitative reverse transcription polymerase chain reaction (qRT‐PCR), respectively.
There were no significant differences in TRAP+ cell numbers or gene expression profiles between these groups. Values represented are
mean±SD and p value was calculated using Student t test (*p< 0.05). [Color figure can be viewed at wileyonlinelibrary.com]
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and gene expression analysis in whole bone RNA
revealed no significant differences in osteoclastic gene
expression or TRAP+ cells regardless of sex (Fig. 5B and
C). This suggests that, as observed ex vivo, dnMAML
reduces osteoclast activity by keeping osteoclasts in an
immature, mononuclear state.
Osteoblast Coupling to Osteoclasts is Maintained in the
Absence of Osteoclast Notch Signaling
Osteoblast precursors from WT mice were cultured in
presence of condition media obtained from either WT or
dnMAML osteoclasts or BMP‐6 as a positive control. Both
ALP activity and mineralization were enhanced by
treatment with osteoclast‐conditioned media regardless
of whether the media came from WT or dnMAML
osteoclasts (Fig. 6A and B). This indicates that osteoclasts
from dnMAML‐expressing precursors do not lose their
ability to stimulate osteoblasts even though they are
deficient in resorptive functionality. However, we cannot
rule out the fact that the condition media might have
some contribution from monocytes in addition to osteo-
clasts serving as a limiting factor for data represented in
Figure 6A and B. These observations were further
evidenced in vivo where osteoblast gene expression was
found to be higher in 6‐month female dnMAML mice and
suggesting that inhibition of Notch pathway in osteo-
clasts does not negatively affect osteoblasts (Fig. 6C;
Supplementary Fig. S2).
LysM‐dnMAML Mice Have Increased Osteoblast Activity
and Bone Strength, But Normal Bone Architecture
Mice were analyzed for morphology of key skeletal
elements and bone architecture using µCT and later
tested mechanically using 3‐point bending. No
changes were observed in any of the parameter
evaluated using µCT (Supplementary Figs. S3A–S6A
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Figure 6. dnMAML osteoclasts stimulate osteogenesis. Osteoclast and osteoblast precursors were obtained from bone marrow of wild‐
type (WT) and dnMAML mice. Osteoblast precursors were cultured in the presence of maintenance media, osteogenic (OG) media
(maintenance media supplemented with β‐glycerol phosphate, ascorbate, and dexamethasone), OG media was combined with conditioned
media from WT or dnMAML osteoclasts, or OG media supplemented with bone morphogenetic protein 6 (BMP‐6) as a positive control.
After 15 days of differentiation, (A) Alkaline phosphatase (ALP) activity was determined using SensoLyte pNPP Alkaline Phosphatase
Assay Kit, and (B) calcium deposits were quantified after alizarin red staining. Both ALP activity and Alizarin Red staining were
significantly increased in all treatment groups compared with maintenance media (*p< 0.05). Similarly, ALP activity and Alizarin Red
staining were significantly increased when OG medium was supplemented with conditioned medium from both WT and dnMAML
osteoclasts as well as with BMP‐6 (†p< 0.05). There was no significant difference between cells treated with WT and dnMAML
conditioned media. (C) Osteoblast genes (ALP, OSX, and RunX2) in 6‐month dnMAML females were significantly increased as measured
by quantitative reverse transcription polymerase chain reaction (qRT‐PCR). Values represented are mean± SD and p value was
calculated using Student t test (*p< 0.05, †p< 0.05).
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and Table S1) while there were significant changes in
rigidity in 6‐month male dnMAML mice (Fig. 7C;
Supplementary Figs. 3B–6B and Table S1). A sig-
nificantly higher number of osteoblast/trabecular area
and osteoblast surface per surface were observed in 6‐
month females (Fig. 7A; Supplementary Figs. S7A‐C
and Table S2). There were also significant increases in
mineral apposition rate and bone formation rate in
6‐month dnMAML females (Fig. 7B, Supplementary
Fig. S8A–C and Table S3). These data indicate that
inhibition of osteoclast Notch signaling does not
produce gross architectural changes at physiological
baseline, but, nevertheless, results in stronger bones
due to increased osteoblast activity, particularly in
older animals.
Inhibition of Notch Signaling in Osteoclasts Results in
Larger Bony Calluses With Increased Mineral Density
Following Traumatic Fracture
We observed that both 3‐month‐old male and female
dnMAML mice showed significant improvements in
fracture healing. These mice displayed significantly higher
bone volume, tissue mineral, and bone mineral densities,
respectively, at 40 DPF (p< 0.05) while no differences were
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Figure 7. dnMAML mice demonstrate increased bone formation rates and bone rigidity. Wild‐type (WT) and dnMAML mice were given
injections of alizarin red and calcein, 8 and 1 days prior to sacrifice, respectively, to label bone mineralizing surfaces. Static and dynamic
histomorphometric analyses were later performed on plastic‐embedded femur sections. (A) Plastic sections were trichrome‐stained, imaged,
and analyzed. There was a significant increase in osteoblast number/trabecular area and osteoblast surface per bone surface percentage in
dnMAML mice. (B) Dynamic histomorphometry using fluorescence microscopy on unstained sections showed significantly higher mineral
apposition and bone formation rates in dnMAML group. Representative data for 6‐month females are depicted. (C) Mechanical testing using
3‐point bending demonstrated bones from dnMAML mice of 6‐month males exhibited significantly higher rigidity. Values represented are
mean±SD and p value was calculated using Student t test (*p< 0.05). [Color figure can be viewed at wileyonlinelibrary.com]
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Figure 8. Inhibition of Notch signaling in osteoclasts results in larger bony calluses during fracture healing. Both 3‐month‐old male
and female mice at 40 days post fracture (DPF) showed significantly larger bony calluses. (A) Three‐dimensional (3D) images and
sectional cut views obtained from µCT in 3‐month males showed (B) significant increases in bone volume, bone volume/total volume,
callus area, tissue mineral density, and bone mineral density. (C) In 3‐month females, there were (D) significant increases in bone volume,
tissue mineral density, and bone mineral density. Values represented are mean± SD and p value was calculated using Student t test
(*p< 0.05). [Color figure can be viewed at wileyonlinelibrary.com]
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Figure 9. Inhibition of Notch signaling results in larger bony callus areas without impacting soft callus formation. Fracture calluses in
3‐month males were Safranin O stained to quantify callus and cartilage areas. Following staining, cartilage‐containing areas are orange/
red, nuclei are black, and background bone and muscle are blue/green. Representative images at (A) 10 days post fracture (DPF) and (B)
20 DPF showed no significant difference in callus or cartilage area between wild‐type (WT) and dnMAML. (C) Callus area was
significantly higher in dnMAML samples at 40 DPF, at which point, no cartilage was visible in either group. Images were captured using
a Nikon Eclipse light microscope at ×20 magnification and were analyzed using Osteomeasure software. Values represented are
mean± SD and p value was calculated using Student t test (*p< 0.05). [Color figure can be viewed at wileyonlinelibrary.com]
Figure 10. Notch inhibition does not impact tartrate‐resistant acid phosphatase (TRAP)+ cell number in fracture calluses. Fracture
calluses from male and female 3‐month‐old wild‐type (WT) and dnMAML mice were TRAP‐stained to evaluate the TRAP+ cell numbers.
No differences in TRAP+ cell number/callus area were observed in either 20 DPFor 40 days post fracture (DPF) samples from (A) 3‐month
males and (B) 3‐month females, respectively. Images were captured using a Nikon Eclipse light microscope at ×20 magnification and were
analyzed using Osteomeasure software. [Color figure can be viewed at wileyonlinelibrary.com]
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observed at prior time points (Fig. 8A‐D, Supplementary
Fig. S9A–C and Table S4). We also observed significantly
higher callus area in 40 DPF 3‐month males but not
females. To further corroborate these findings, histology
was performed using paraffin‐embedded samples. There
was a significant increase in callus area in 40 DPF group
(p< 0.05) for the males but not for female group (Fig. 9,
Supplementary Fig. S10 and Table S4) while no differ-
ences in osteoclasts numbers/callus area were observed in
TRAP‐stained sections (Fig. 10). This indicates that Notch
inhibition in osteoclasts does not affect their cellular
number but, rather, their function.
DISCUSSION
Inhibition of Notch signaling or the genes it regulates
in osteoclasts may be a viable method for reducing bone
resorption while maintaining bone formation. Systemic
inhibition of Notch signaling through global, inducible
expression of dnMAML produces a net inhibitory effect
on fracture healing due to the deleterious effects of
dnMAML expression on bone formation.50 Here, we
investigated the effects of Notch signaling inhibition in
osteoclast precursors on resting bone characteristics
and the fracture healing process in vivo. Congruent
with prior studies, we found that Notch inhibition via
dnMAML suppressed osteoclast function both in vitro
and in vivo without significant reduction of early
osteoclastic gene expression or coupled osteoblast
activity. From our ex vivo experiments, we hypothesize
that dnMAML‐expressing osteoclast precursors un-
dergo early differentiation toward osteoclasts but fail
to fuse and persist as mononuclear TRAP+ cells, though
this morphological difference is difficult to ascertain in
vivo. Furthermore, where alterations in osteoblast
number or function were observed, these parameters
were increased, and this resulted in increased bone
formation rate and strength. With this increased
osteoblast activity, however, we did not observe any
significant alterations in bone architecture, which
suggests that, while dnMAML‐expressing osteoclasts
have reduced activity, their resorptive function is
sufficient for physiological bone remodeling.
Despite modest changes at physiological baseline,
LysM‐dnMAML mice showed significant increases in
bony callus and mineralization compared with WT.
Unaltered TRAP+ cell numbers in the healing fractures
suggests that, as with uninjured animals, the increase
in bone is more likely due to reduced resorptive activity
rather than cell number. Taken with the physiological
remodeling data, our work suggests that osteoclast
Notch signaling is dispensable with respect to level of
osteoclast activity required for normal remodeling.
Thus, therapeutic inhibition of osteoclast Notch sig-
naling could result in reduction of osteoclast activity in
regions of the skeleton where that activity would have
been pathologically elevated while sparing restorative
remodeling elsewhere.
While previous clinical studies utilizing bisphospho-
nates and RANKL inhibition51–53 suggested that
osteoclast inhibition does not significantly impact
fracture callus parameters, the conclusions of these
studies cannot distinguish between osteoclast function
and osteoclast number as both interventions reduce
osteoclast number by either triggering osteoclast
apoptosis (bisphosphonates) or inhibiting osteoclasto-
genesis from an early stage (RANKL inhibition). The
negative findings of these studies may be due to a
concomitant decrease in osteoblast activity following
reduction in osteoclast number, which would effectively
neutralize any positive effect that osteoclast inhibition
might have had on callus size and mineralization.
Thus, while reduction of osteoclast number can pro-
mote increased bone mass and decreased fracture risk
in the short term, long‐term suppression of bone
remodeling is a source of concern.54,55 Reduction of
osteoclast activity without impacting their coupling to
osteoblasts, as we have demonstrated with osteoclast‐
specific inhibition of Notch signaling, has the potential
to alleviate concerns regarding long‐term anti‐resorp-
tive therapy and produce larger, potentially more stable
fracture calluses through the preservation of osteoclast‐
stimulated osteogenesis in the context of reduced bone
resorption.
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